When Direct Compression Constraints Bound Quaternary Ammonium Tablet Manufacture

In oral tablet manufacturing for a benzyl triethyl ammonium chloride Pharma Grade API, the direct compression or dry granulation route is selected only after the particle size distribution of the active ingredient has been matched to the excipient carrier, because the quaternary ammonium salt exhibits hygroscopic behaviour and can adhere to stainless steel tooling under prolonged dwell times. The compliance framework includes USP <905> Uniformity of Dosage Units, USP <701> Disintegration, USP <1216> Tablet Friability, ICH Q3D Elemental Impurities, and in-process sampling under FDA 21 CFR 211.110. The addition ratio is not a fixed excipient percentage; it is calculated from the target dose divided by the tablet core mass. For a batch record requiring a 10 mg dose in a 400 mg core, the active mass fraction is 2.5% w/w, whereas a 5 mg dose in the same core reduces the fraction to 1.25% w/w. Published pharmacopoeial monographs for this specific quaternary ammonium API do not impose a universal formulation percentage, so batch-specific calculation is mandatory. In production, the API is pre-blended with 0.5–1.0 part of microcrystalline cellulose or lactose monohydrate and passed through a conical mill fitted with a 0.6 mm rasp screen at 1,500 rpm to break agglomerates; the pre-blend is then charged into a 200 L V-blender with the remaining fillers and disintegrants and mixed for 15 min at 12 rpm. Magnesium stearate is added at 0.5% w/w via a 0.5 mm screen and mixed for an additional 3 min to minimise lower punch sticking. Compression is carried out on a rotary tablet press with a paddle feeder, pre-compression force 4–6 kN, main compression force 8–18 kN, and turret speed 30–60 rpm; tablet hardness is maintained at 70–120 N, friability is held below 1.0% w/w, and thickness variation is limited to ± 5% of the target thickness. Low-dose tablet lines frequently exhibit demixing when the API fraction is below 1.0% w/w; this failure mode is managed by keeping the blender fill volume between 40% and 60% of total capacity and by avoiding free-fall transfer steps after lubrication. The terminal finished form is an immediate-release film-coated tablet, typically coated in a side-vented pan at inlet air temperature 45–60°C to a weight gain of 2–3% w/w, then packed in PVC/PVDC blister or HDPE bottles with desiccant.

In hard capsule filling, the same active is handled as a dry powder or low-shear granulate, but the critical processing difference is flow consistency through a dosator or tamping pin mechanism rather than die fill behaviour. Compliance for this dosage form includes USP <711> Dissolution, USP <1174> Powder Flow, ICH Q3D Elemental Impurities, and batch release testing under FDA 21 CFR 211.165. The API addition level is derived from the label dose and the total fill mass; a 5 mg dose in a 300 mg fill gives 1.7% w/w, and this fraction may be lower for reduced unit doses. Because the quaternary ammonium cation carries a permanent positive charge and the chloride counterion is sensitive to atmospheric moisture, the filling suite is maintained at 35–45% RH and 18–22°C, while ionised air is directed at the capsule hopper discharge to reduce static attachment of the low-percentage active to the dosator nozzle. On a tamping-pin capsule filling machine, the powder bed height is controlled at 30–50 mm, and the tamping pin penetration depth is set between 0.4 mm and 0.8 mm depending on the Carr index; fill weight RSD is held below 3.0% by adjusting pin stroke speed and using a 2.5 mm mesh screen for the lubricant. Batch-to-batch variance is frequently caused by capsule shell moisture variation: gelatin capsules are held at 13–16% w/w water content, while HPMC capsules are conditioned to 3–5% w/w water content prior to filling. The filled capsules are dedusted on a rotating brush line, passed through a metal detector set to 0.8 mm ferrous and 1.0 mm stainless steel spheres, and then weighed on a checkweigher at ± 3% of target fill mass. The terminal finished dosage form is a hard gelatin or HPMC capsule, directly packaged in cold-form aluminium foil blisters or bottles with desiccant.

Granule Flow and Moisture Control in Oral Granule Manufacture

For oral granule presentation in single-dose sachets or dry suspension bottles, benzyl triethyl ammonium chloride Pharma Grade API is incorporated by wet granulation rather than dry blending, because the larger granule surface area and low-dose active demand a uniform distribution that survives short-term storage under tropical humidity. The quality standards for this finished form are USP <905> Uniformity of Dosage Units for unit-dose packages, ICH Q3D Elemental Impurities, ICH Q3C Residual Solvents if organic granulation fluids are used, and FDA 21 CFR 211.192 for out-of-specification investigations. The addition ratio is computed from the dose per sachet and the filled granule mass; for a 20 mg dose in a 2,000 mg granule fill, the active fraction is 1.0% w/w. Wet granulation is carried out in a high-shear mixer with a 65 L bowl and a 10–12 kg batch size. The impeller tip speed is held at 4–6 m/s, the chopper is run at 1,500–2,500 rpm, and purified water or a pre-gelatinised starch slurry is sprayed at 80–120 g/min using a peristaltic pump with a pressure-fed nozzle. The granulation endpoint is determined by impeller torque increase to 1.5–2.5 Nm rather than by subjective hand-squeeze assessment; over-granulation beyond 3.0 Nm generates dense agglomerates that later resist disintegration testing. The wet mass is discharged through a 6 mm aperture and dried in a fluid bed dryer with inlet air temperature 55–70°C and exhaust air 30–40°C until loss on drying reaches 2.0–2.5% w/w. Dried granules are sized through a 1.0 mm screen and blended with flavour, sweetener, and an anti-caking agent such as colloidal silicon dioxide at 0.2% w/w. The terminal finished type is a single-dose oral granule in laminated aluminium sachets or a dry suspension granule for reconstitution in HDPE bottles with a measuring scoop.

Terminal sterilisation of a quaternary ammonium salt solution demands a controlled aqueous formulation and a container closure system that minimises ion exchange, stopper extractables, and headspace oxidation. The compliance framework for this injectable dosage form includes USP <1> Injections, USP <85> Bacterial Endotoxins, USP <788> Particulate Matter in Injections, ICH Q3C Residual Solvents, FDA 21 CFR 210 and 211, and ISO <14644-1> Class 5 controlled environment for filling operations. The API addition concentration is expressed on a weight-per-volume basis; for a filling formula requiring 2 mg/mL in a 2 mL fill volume, the concentration is 0.2% w/v. Published clinical dose data for this specific API in injectable form is limited, so the concentration is not fixed by a compendial monograph and must be justified by the marketing authorisation holder through stability and toxicology data. The solution is prepared in a jacketed stainless steel tank with WFI at 20–25°C under nitrogen overlay, stirred at 200–300 rpm for 10–15 min until complete dissolution, and the pH is adjusted with dilute hydrochloric acid or sodium hydroxide to 5.5–6.5. The bulk solution is filtered through a 0.45 µm prefilter and a 0.22 µm polyethersulfone membrane filter immediately before aseptic filling; filter integrity is tested by bubble point before and after filtration. Filling is performed on a peristaltic or rotary piston line targeting ± 3% fill volume accuracy, followed by autoclaving at 121°C with an F0 value of at least 8 minutes for a solution-stable product. Visible particulate failures are often traced to silicone oil migration from rubber stoppers; stoppers are therefore washed with WFI and siliconised at 0.5–1.5 mg silicone per stopper before insertion. The terminal finished type is a small-volume injectable solution in 2R Type I borosilicate glass vials with chlorobutyl rubber stoppers and aluminium overseals.

What Limits Residual Moisture and Cake Elegance in Lyophilised Quaternary Ammonium Formulations?

Lyophilisation is selected when the quaternary ammonium API is insufficiently stable in aqueous solution at terminal sterilisation temperatures or when long-term hydrolytic degradation of the chloride counterion is observed in packaged solution vials. The relevant compliance controls are USP <1> Injections, USP <788> Particulate Matter in Injections, USP <921> Water Determination by Karl Fischer, USP <1207> Container Closure Integrity Testing, ICH Q3D Elemental Impurities, and FDA 21 CFR 211.94 for container and closure systems. The pre-lyophilisation solution concentration is calculated on a w/v basis; a formulation containing 1 mg/mL active and 4% w/v mannitol as a crystalline bulking agent gives an API fraction of 0.1% w/v before drying. Because low API mass fractions can lead to poor cake mechanical strength, a bulking agent is required to prevent blow-out during vacuum stoppering; mannitol crystallisation is promoted by an annealing step at -15°C for 2–4 h after initial freezing to -45°C at 0.5–1.0°C/min. Primary drying is performed at a shelf temperature of -25°C to -20°C and a chamber pressure of 80–150 µbar, holding the product temperature below the collapse onset determined by freeze-drying microscopy; if product temperature exceeds -20°C, microcollapse produces a shrunken cake and increased residual moisture variability. Primary drying endpoint is established by comparative pressure measurement or thermocouple response, after which secondary drying raises the shelf temperature to 25–40°C for 6–12 h until residual moisture is < 3.0% w/w by USP <921> Karl Fischer. Containers are stoppered under vacuum or nitrogen at 800 mbar absolute pressure, and container closure integrity is verified by vacuum decay per USP <1207> at a pressure differential of 1.5× the fill volume. Batch records show that the dominant failure mode in scale-up is not the drying phase but the filling line hold time; solution hold times longer than 4 h at room temperature before loading can increase sub-visible particle counts above the USP <788> acceptance limits for large-volume parenterals. The terminal finished type is a sterile lyophilised cake in Type I glass vials for reconstitution with WFI or saline before injection.